Down syndrome (DS) is associated with early onset of neuropathology that is indistinguishable from Alzheimer disease (AD), and is typically followed by cognitive decline two decades later. A recent study has reported that the AD drug memantine failed to improve cognitive performance and function in middle-aged patients with DS.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer’s-like memory deficits in the Ts65Dn mouse model of Down syndrome
Scientific Reports Open Access 03 April 2017
-
Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial
Translational Psychiatry Open Access 17 July 2012
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Patterson, D. & Costa, A. C. Down syndrome and genetics—a case of linked histories. Nat. Rev. Genet. 6, 137–147 (2005).
Zigman, W. B. & Lott, I. T. Alzheimer's disease in Down syndrome: neurobiology and risk. Ment. Retard. Dev. Disabil. Res. Rev. 13, 237–246 (2007).
Mohan, M., Carpenter, P. K. & Bennett, C. Donepezil for dementia in people with Down syndrome. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD007178. http://dx.doi.org/10.1002/14651858.CD007178.pub2 (2009).
Hanney, M. et al. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet 379, 528–536 (2012).
Margallo-Lana, M. L. et al. Cognitive decline in Down syndrome. Arch. Neurol. 60, 1024 (2003).
Holland, A. J. in Dementia, Aging, and Intellectual Disabilities: A Handbook (eds Janicki, M. P. & Dalton, A. J.) 183–197 (Taylor & Francis, Philadelphia, 1999).
Pennington, B. F., Moon, J., Edgin, J., Stedron, J. & Nadel, L. The neuropsychology of Down syndrome: evidence for hippocampal dysfunction. Child Dev. 74, 75–93 (2003).
Costa, A. C. On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome. Dev. Neurosci. 33, 414–427 (2011).
Scott-McKean, J. J. & Costa, A. C. Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine. Learn. Mem. 18, 774–778 (2011).
Lockrow, J., Boger, H., Bimonte-Nelson, H. & Granholm, A. C. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav. Brain Res. 221, 610–622 (2010).
Acknowledgements
A. C. Costa is supported in part by NIH grant RO1-HD056235, the Linda Crnic Institute, and the Coleman Institute for Cognitive Disabilities.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
A. C. Costa has received grant/research support from Forest Research Institute.
Rights and permissions
About this article
Cite this article
Costa, A. Treatment of Alzheimer disease in Down syndrome. Nat Rev Neurol 8, 182–184 (2012). https://doi.org/10.1038/nrneurol.2012.40
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2012.40
This article is cited by
-
Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer’s-like memory deficits in the Ts65Dn mouse model of Down syndrome
Scientific Reports (2017)
-
Prospects for Improving Brain Function in Individuals with Down Syndrome
CNS Drugs (2013)
-
Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial
Translational Psychiatry (2012)
